{"entity":{"id":"benmelstobart","kind":"drug","name":"Benmelstobart","aka":[],"tldr":"Benmelstobart is Chia Tai Tianqing's PD-L1 antibody, approved in China in 2024 for extensive-stage small-cell lung cancer in combination with anlotinib and chemotherapy.","summary":"Benmelstobart (TQB2450) is a humanised anti-PD-L1 antibody developed by Chia Tai Tianqing, part of Sino Biopharmaceutical. The NMPA approved it in 2024 for first-line treatment of extensive-stage small-cell lung cancer together with the multi-kinase inhibitor anlotinib and platinum-etoposide chemotherapy, on the ETER701 phase 3 trial, which reported longer overall survival than chemotherapy alone. It is the first checkpoint inhibitor approved in a four-drug first-line regimen for this cancer.","status":"approved","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of benmelstobart","url":"https://clinicaltrials.gov/search?intr=TQB2450"}],"tags":["china","nmpa-approved"],"related":[],"cancers":["sclc","extensive-stage-sclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pdl1"],"drugs":[],"companies":["sino-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo China deep dive","editedOn":"2026-09-16"},"code":"TQB2450","modality":"Anti-PD-L1 monoclonal antibody","mechanism":"Blocks PD-L1 on tumour and immune cells so that T cells are no longer switched off at the tumour.","approvals":[{"region":"CN","year":2024,"indication":"Extensive-stage small-cell lung cancer, first line, with anlotinib and platinum-etoposide chemotherapy"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/benmelstobart/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"company":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}],"trial":[{"id":"nct06469879","kind":"trial","name":"A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients","route":"/trials/nct06469879/"},{"id":"nct07538271","kind":"trial","name":"A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer","route":"/trials/nct07538271/"},{"id":"nct07371663","kind":"trial","name":"An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors","route":"/trials/nct07371663/"},{"id":"nct06992336","kind":"trial","name":"Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy","route":"/trials/nct06992336/"},{"id":"nct07548177","kind":"trial","name":"Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma","route":"/trials/nct07548177/"},{"id":"nct07109167","kind":"trial","name":"The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors","route":"/trials/nct07109167/"},{"id":"nct06955325","kind":"trial","name":"Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations","route":"/trials/nct06955325/"}]}}